Associated Papers
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Correlation of TP53 Genetic Alterations with p53 Immunohistochemical Expression and Their Prognostic Significance in DLBCL.
Chen C et al.
Current Oncology (toronto, Ont.), 2025
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Kumar A et al.
Blood, 2025
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies.
Mahmoud AA et al.
Plos One, 2025
Multiregion exome sequencing indicates a monoclonal origin of esophageal spindle-cell squamous cell carcinoma.
Wang Y et al.
The Journal of Pathology, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Comprehensive classification of TP53 somatic missense variants based on their impact on p53 structural stability.
Tam B et al.
Briefings in Bioinformatics, 2024
Artificial Intelligence-Driven Morphology-Based Enrichment of Malignant Cells from Body Fluid.
Mavropoulos A et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2023
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Ter Brugge P et al.
Nature Communications, 2023
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations.
Tang Y et al.
Cell Reports, 2022
The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y et al.
Bmc Cancer, 2022
Genetic and epigenetic characterization of posterior pituitary tumors.
Schmid S et al.
Acta Neuropathologica, 2021
Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C et al.
Scientific Reports, 2021
BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes.
Nikanjam M et al.
Molecular Cancer Therapeutics, 2021
Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.
Quan VL et al.
The Journal of Investigative Dermatology, 2020
Identification of relevant genetic alterations in cancer using topological data analysis.
Rabadán R et al.
Nature Communications, 2020
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
Lowder CY et al.
Surgical Oncology, 2020
Immunogenicity and Immune Silence in Human Cancer.
Yarmarkovich M et al.
Frontiers in Immunology, 2020
Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer.
Boyarskikh UA et al.
Frontiers in Oncology, 2020
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer.
Kwon SM et al.
Scientific Reports, 2019
Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma.
Ma J et al.
Bmc Cancer, 2018
Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.
Bartels S et al.
Virchows Archiv : an International Journal of Pathology, 2018
TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis.
Dobashi A et al.
Oncotarget, 2018
Integrative genomic and transcriptomic analysis of leiomyosarcoma.
Chudasama P et al.
Nature Communications, 2018
Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.
Harvey NT et al.
Pathology, 2016
Mutant GDF15 presents a poor prognostic outcome for patients with oral squamous cell carcinoma.
Ma J et al.
Oncotarget, 2016
Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.
Clynick B et al.
The Journal of Molecular Diagnostics : Jmd, 2015
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.
Pilat N et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015
Predicting the functional impact of protein mutations: application to cancer genomics.
Reva B et al.
Nucleic Acids Research, 2011
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z et al.
Plos One, 2008